BUY Glenmark Pharmaceuticals — Kush Bohra, 25 Aug 2026

byKush BohraHorizon: NA (inferred 1–3 months)25 Aug 2026via NDTV Profit

Entry₹2,391.7Inferred

Target₹2,510

Stop loss₹2,325-2.79% risk

Exit₹2,51028 Aug 2026, 12:08 pm

Target hit+4.95%0.00%upside left

Follow Kush Bohra for new calls(40% target hit, 10 closed calls)Get alerts Watch GLENMARK for new buy/sell callsGet alerts See 2 active Short-term calls on GLENMARK

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 28 Aug 2026

9 supporting5 neutral2 opposing

Supports the BUY call (9)

3 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·27 Aug · yesterday

Glenmark Pharmaceuticals Inc., USA has launched a new Calcium Gluconate Injection product in various strengths and vial sizes.

BSE · Company Update·21 Aug · 1w ago

Glenmark Pharmaceuticals has received approval from the U.S. FDA for its Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray.

BSE · Company Update·20 Aug · 1w ago

2 other SEBI-registered advisors have active short-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·20 Aug · 1w ago

Glenmark Pharma Q1 Revenue Beats Estimates, EBITDA Margins Seen Rising

NewsGoogle News·4 Aug · 3w ago

Neutral / worth noting (5)

Glenmark Pharma, Mastek, Triveni Engineering Dividends: Last Day To Buy Shares To Qualify

NewsNdtv-Profit·28 Aug · today

Glenmark USA has agreed to a settlement of $15.28 million to resolve antitrust and consumer protection lawsuits related to price-fixing allegations. The company denies all allegations and states the s

BSE · Company Update·11 Aug · 2w ago

Glenmark Pharma Q1 FY27 Results and Brokerage Outlook

NewsGoogle News·4 Aug · 3w ago

Glenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

NSE · Outcome of Board Meeting·31 Jul · 4w ago

The Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026

BSE · Board Meeting·31 Jul · 4w ago

Weighs against the BUY call (2)

Glenmark Pharma US arm agrees to $15.28 million settlement with Humana over antitrust lawsuits

NewsCnbc-Tv18·12 Aug · 2w ago

1 advisor has an active long-term SELL call on this stock

Advisor consensus · adjacent horizon·3 Feb · 7mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.